CD200 and neoplasm: Noteworthily, the high-risk group indicated lower expression levels of CD200, NRP1, and TNFRSF14, suggesting that tumor cells might evade immune surveillance through inhibiting the function of these immune checkpoint genes, which could subsequently affect patient prognosis.